Mode
Text Size
Log in / Sign up
N/A N=77

Using Affective Differences to Predict Response to Behavioral Treatment for Major Depressive Disorder

Depression

Enrolled (actual)
77
Serious AEs
Results posted
Jan 2018
Primary outcome: Primary: Analyses of Covariance to Test for Group Differences (MDD vs. Healthy) on Clinician-rated Depression Severity After 16 Weeks of Behavioral Activation Psychotherapy, Controlling for Baseline Depression Severity. — 14.1; 2.7 units on a scale — p=0.05

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Behavioral Activation (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Northwestern University
Primary completion
Apr 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Analyses of Covariance to Test for Group Differences (MDD vs. Healthy) on Clinician-rated Depression Severity After 16 Weeks of Behavioral Activation Psychotherapy, Controlling for Baseline Depression Severity.
14.1; 2.7 0.05
PRIMARY
Analyses of Covariance to Test for Group Differences (MDD vs. Healthy) on Patient-rated Depression Severity After 16 Weeks of Behavioral Activation Psychotherapy, Controlling for Baseline Depression Severity.
16.9; 3.0 <0.05 sig
PRIMARY
Pre-treatment Frontal EEG Asymmetry Score as a Predictor of Negative Affect at Post-treatment
0.43; 0.16 .02 sig
PRIMARY
A Two Level Hierarchical Model Testing the Association Between Negativity Bias Change During BA Treatment With Patient-reported Depression Severity (Week 16 IDS-SR).
-3.43 <0.05 sig

Summary

This study will determine how people with depression differ from healthy people in brain activity and interpreting emotions, both before and after receiving a psychotherapy treatment.

Eligibility Criteria

Inclusion Criteria

  • Healthy participants should have no lifetime history of psychiatric disorder
  • Depressed participants should have a current diagnosis of major depressive disorder, as defined by the DSM-IV

Exclusion Criteria

  • History of bipolar affective disorder
  • History of psychosis
  • Current non-psychotic Axis I disorder, if it constitutes the predominant aspect of the clinical presentation and immediately requires treatment other than that offered in the study
  • History of substance dependence within the past 6 months
  • Antisocial, borderline, schizotypal, or schizoid personality disorders
  • Evidence of any medical disorder or condition that could cause depression or preclude the use of study treatments
  • Current treatment with catecholaminergic antihypertensive medication, such as reserpine, beta-blockers, clonidine, and alphamethyldopa
  • Current use of antidepressant medication
  • Clear indication of secondary gain
  • Current suicide risk sufficient to preclude treatment on an outpatient basis
  • Severe, unstable concurrent psychiatric conditions likely to require hospitalization within 6 months of study entry
  • Already receiving a targeted psychotherapy aimed at depression
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00909220). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search